Trials in Boston, Massachusetts
Here are the top 3 medical studies for retinitis pigmentosa in Boston, Massachusetts
Popular Filters
Phase 3 Trials
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Gene Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
Glutamate Modulator
Troriluzole for Spinocerebellar Ataxia
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial is testing whether a medication called Troriluzole can help people with spinocerebellar ataxia by balancing a brain chemical to prevent damage. Troriluzole is related to riluzole, which has been shown to prolong survival and slow functional deterioration in patients with ALS.
Gene Therapy
BIIB111 for Choroideremia & BIIB112 for X-Linked Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial will compare the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111, with untreated control participants who have exited the STAR (NCT03496012) study. The trial will also compare BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112.
Trials With No Placebo
Gene Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
Gene Therapy
BIIB111 for Choroideremia & BIIB112 for X-Linked Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial will compare the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111, with untreated control participants who have exited the STAR (NCT03496012) study. The trial will also compare BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.